# Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis

> **NCT04074590** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 23 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** LYS006
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04074590
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-03
- **Primary completion:** 2022-11-07
- **Final completion:** 2022-11-07
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Sponsor decision due to strategic considerations
- **Last updated:** 2024-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04074590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04074590, "Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04074590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*